Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients

This study has been completed.
Sponsor:
Information provided by:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT00213798
First received: September 13, 2005
Last updated: August 29, 2011
Last verified: August 2011
  Purpose

The majority of lung cancer patients have a tumor-derived genetic alteration in circulating plasma DNA that could be exploited as a diagnostic tool. The aim of this study is to evaluate if plasma DNA can be used as a valuable non invasive test to monitor disease progression without assessing the tumor.


Condition Intervention
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Procedure: Biopsy samples

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Official Title: Detection of Plasma DNA by Allelotyping in Non Small Cell and Small Cell Lung Cancer Patients. Evolution During Treatment and Follow-up.

Resource links provided by NLM:


Further study details as provided by University Hospital, Strasbourg, France:

Estimated Enrollment: 200
Study Start Date: December 2003
Study Completion Date: August 2011
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Presence of lung tumor to use fiberoscopy or surgical intervention for diagnosis.
  • No lung instability.
  • Individuals give all informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00213798

Locations
France
Service de Chirurgie Thoracique, Hôpital Civil
Strasbourg, France, 67091
Service de Pneumologie, Hôpital Civil
Strasbourg, France, 67091
Service de Pneumologie, Hôpital de Hautepierre
Strasbourg, France, 67098
Service de Pneumologie, Hôpital Lyautey
Strasbourg, France, 67000
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Principal Investigator: Michèle BEAU-FALLER, MD Service de Pneumologie, Hôpital de Hautepierre
  More Information

No publications provided

Responsible Party: Emmanuel LAVOUE, Directeur Adjoint, University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT00213798     History of Changes
Other Study ID Numbers: 2731
Study First Received: September 13, 2005
Last Updated: August 29, 2011
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Strasbourg, France:
Lung cancer
plasma DNA
allelotyping
follow-up
Prospective Study
Non-Small Cell Lung Cancer
Small Cell Lung Cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Small Cell Lung Carcinoma
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms

ClinicalTrials.gov processed this record on November 25, 2014